Regeneron/Bayer Partnership Seeks To Build Upon Eylea's Success
This article was originally published in The Pink Sheet Daily
Latest ophthalmologic collaboration between the partners seeks to create an Eylea successor by combining aflibercept with an Ang2 antibody.
You may also be interested in...
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.
Speaking at the J.P. Morgan meeting in January, Regeneron CEO Leonard Schleifer says the company is exploring many opportunities to build the franchise around its successful wet AMD drug Eylea. In the fourth quarter, the drug racked up $400 million in U.S. sales, beating expectations.
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.